Product Description
BioChemics was developing bc-dn-01, a topical drug, for the treatment of Painful Diabetic Neuropathy (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01793350)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioChemics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Peripheral Nervous System Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01793350 |
BC-222 | P2 |
Withdrawn |
Peripheral Nervous System Diseases |
2014-10-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|